Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

NCT05662319 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05662319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 1, 2023
Completion date
January 25, 2029
Enrollment
91 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia